TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
* Predominant stress urinary incontinence by self-report,examination and test;~* Urethral hypermobility;~* Eligible for both surgical procedures;~* Ambulatory;~* Not pregnant;~* \>12 months post-partum;~* No systemic disease known to affect bladder function;~* No current chemotherapy or radiation therapy;~* No urethral diverticulum, augmentation cytoplasty, or artificial sphincter;~* No recent pelvic surgery;~* Available for follow-up and able to complete study assessments;~* Signed informed consent.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Burch (Type: OTHER): The Burch colposuspension
- Sling (Type: OTHER): Pubovaginal sling, using autologous rectus fascia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients 12 years of age and older with a 2 year history of moderate to severe seasonal allergic rhinitis~* Must be in generally good health~* Must meet minimum symptom requirements, as specified in the protocol~* Must be wiling and able to provide informed consent and to participate all study procedures~* Positive skin test to a prevalent spring allergen~Exclusion criteria:~* On nasal examination,the presence of nasal mucosal erosion, nasal ulceration or nasal septal perforation~* Nasal disease likely to affect the deposition of the medication or evaluation, such as sinus infection, nasal polyps or severe deviated septum~* Nasal or sinus surgery within the previous 6 months~* Chronic sinus infection (more than 3 per year)~* Planned travel outside the study area during the study period~* Use of any investigational drug within 30 days of the first visit~* Hypersensitivity (bad reaction) to azelastine hydrchloride nasal spray (Astelin), or fluticasone propionate nasal spray (Flonase)~* Women who are not using an acceptable method or birth control~* Women who are pregnant or nursing~* Upper respiratory tract infection such as common cold, flu, sinus infection within 2 weeks of first study visit~* Asthma or other lung diseases such as COPD. Mild asthma symptoms may be considered after consultation with the investigator~* Irregular heartbeat or other symptomatic heart conditions~* History of alcohol or drug abuse~* History of glaucoma~* Use of medications that could affect the study results

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- fluticasone propionate (Type: ACTIVE_COMPARATOR): None
- azelastineHcl/fluticasone propionate (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- azelastine Hcl (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnetic Resonance Imaging in Subjects With Gouty Tophi

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with gout and at least one tophi.~Exclusion Criteria:~* Unable to undergo MRI.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Volumes/measurements of tophi determined by serial MRIs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Relevant Inclusion and Exclusion Criteria are listed below.~Inclusion Criteria~* Partial-onset seizures with or without secondary generalization. The final determination shall be made by the Investigator based on a clinical description of the seizures and previous diagnostic testing that includes, at a minimum, video/clinical EEG that captured at least one ictal event.~* Anticipated average of 6 or more partial-onset seizures (with or without secondary generalized seizures) per month during the Baseline Phase, with no more than 30 days between seizures during the Baseline Phase.~* Refractory to antiepileptic drugs (AEDs). Patients will be considered refractory if they have failed at least three AEDs due to lack of efficacy.~* Receiving one to four currently marketed AEDs~* Be between 18 and 65 years of age at the time of lead implant~Exclusion Criteria:~* Multilobar (\>3 different lobes) anatomic areas of seizure onset~* Symptomatic generalized epilepsy~* Previous diagnosis of psychogenic/non-epileptic seizures~* Presence of implanted electrical stimulation medical device anywhere in the body (e.g., cardiac pacemakers, spinal cord stimulator) or any metallic implants in the head (e.g., aneurysm clip, cochlear implant). Vagal nerve stimulators are allowed if the device has been turned off for at least 30 days prior to the Baseline Week -12 visit and the patient agrees to have the generator explanted prior to or at the time of the Kinetra Neurostimulator implant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Active Stimulation
- 2 (Type: SHAM_COMPARATOR): No Stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Adults with either active or a history of non-valvular atrial fibrillation or flutter with the planned or existing use of an oral anticoagulant for prophylaxis of thromboembolism. In addition, subjects must have had an acute coronary syndrome or percutaneous coronary intervention with a stent within the prior 14 days~* Planned use of antiplatelet agents for at least 1 to 6 months~* Males and Females ≥ 18 years of age~* Women of childbearing potential must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug~Exclusion Criteria:~* Conditions other than atrial fibrillation that require chronic anticoagulation. (e.g. prosthetic mechanical heart valve)~* Severe renal insufficiency (serum creatinine \> 2.5 mg/dL or a calculated creatinine clearance \< 30 mL/min~* Patients with a history of intracranial hemorrhage~* Patients have had or will undergo Coronary arterial bypass graft (CABG) for their index acute coronary syndrome (ACS) event~* Patients with known ongoing bleeding and patients with known coagulopathies~* Any contraindications or allergies to VKA, apixaban, or to intended P2Y12 antagonists or to aspirin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Apixaban (Type: ACTIVE_COMPARATOR): 5 mg or 2.5 mg Apixaban tablets orally twice per day
- Vitamin K Antagonist (Type: ACTIVE_COMPARATOR): VKA tablets orally once daily
- Acetylsalicylic acid film coated tablet (Type: PLACEBO_COMPARATOR): 81 mg Acetylsalicylic acid film coated tablet orally once daily
- Placebo matching Acetylsalicylic acid film coated tablet (Type: PLACEBO_COMPARATOR): Placebo matching Acetylsalicylic acid film coated tablet once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinically stable, in the opinion of the investigator~* CVC occlusion~* Able to have fluids infused at the volume necessary to instill study drug into the CVC~Exclusion Criteria:~* Able to have 3 mL of blood (patients weighing ≥ 10 kg) or 1 mL of blood (patients weighing \< 10 kg) withdrawn from the selected study CVC following patient repositioning~* Selected study CVC inserted \< 2 days prior to treatment~* Selected study CVC known to be dysfunctional for \> 7 days~* Selected study CVC implanted specifically for hemodialysis (HD)~* Use of a power injector on the selected study CVC during the study~* Evidence of mechanical, non-thrombotic occlusion of the selected study CVC (e.g., kink in the catheter or suture constricting the catheter)~* Previously treated in this study or any tenecteplase catheter clearance trial~* Use of any investigational drug or therapy within 28 days prior to treatment~* Use of a fibrinolytic agent (e.g., alteplase, tenecteplase, reteplase, or urokinase) within 24 hours prior to treatment~* Known to be pregnant or breastfeeding at screening~* CVC with known or suspected infection~* History of any intracranial hemorrhage, aneurysm, or arteriovenous malformation~* Use of heparin (unfractionated or low molecular weight) within 24 hours prior to treatment, except for use of intermittent or low-dose, continuous infusion of heparin to maintain catheter or vessel patency~* Use of warfarin within 7 days prior to treatment, except for low-dose warfarin used for prophylaxis~* Initiation of or increase in dose of Plavix® (clopidogrel bisulfate) within 7 days prior to treatment~* At high risk for bleeding events or embolic complications (i.e., recent pulmonary embolus, deep vein thrombosis, endarterectomy, or clinically significant right-to-left shunt) in the opinion of the investigator, or with known condition for which bleeding constitutes a significant hazard~* Known hypersensitivity to tenecteplase or any component of the formulation

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo + Tenecteplase + Tenecteplase (PTT) (Type: PLACEBO_COMPARATOR): None
- Tenecteplase + Tenecteplase + Placebo (TTP) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Have been diagnosed with type 2 diabetes mellitus (T2DM).~* Are naïve to diabetes injectable therapies and have not used any oral antihyperglycemic medications (OAMs) during the 3 months preceding screening.~* Have HbA1c between ≥7.0% and ≤9.5%.~* Be of stable weight (± 5%) for at least 3 months before screening.~* Have a BMI ≥23 kilograms per meter squared (kg/m²) at screening.~Exclusion Criteria:~* Have type 1 diabetes mellitus.~* Have had chronic or acute pancreatitis any time prior to study entry.~* Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative diabetic retinopathy requiring acute treatment.~* Have disorders associated with slowed emptying of the stomach, or have had any stomach surgeries for the purpose of weight loss.~* Have an estimated glomerular filtration rate \<30 mL/minute/1.73 m².~* Have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months.~* Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2.~* Have been taking weight loss drugs, including over-the-counter medications during the last 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 5 mg Tirzepatide (Type: EXPERIMENTAL): Participants received 5 milligrams (mg) of tirzepatide as subcutaneous injection once a week.
- 10 mg Tirzepatide (Type: EXPERIMENTAL): Participants received 10mg of tirzepatide as subcutaneous injection once a week.
- 15 mg Tirzepatide (Type: EXPERIMENTAL): Participants received 15mg of tirzepatide as subcutaneous injection once a week.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo as subcutaneous injection once a week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Outcomes of Stem Cells for Cerebral Palsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cerebral palsy of any types caused by oxygen deprivation.~Exclusion Criteria:~* Epilepsy~* Hydrocephalus with ventricular drain~* Coagulation disorders~* Allergy to anesthetic agents~* Severe health conditions such as cancer, failure of heart, lung, liver or kidney~* Active infections

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Stem cell transplantation (Type: EXPERIMENTAL): 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 3 months afterward

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic HIV infection with plasma RNA viral burden of HIV \> 2,000 copies/ml obtained in the month prior to randomization.~* Ages 18 years or older.~* Women with childbearing potential should use an effective contraceptive method.~* The subjects should give their written informed consent.~* The subjects should provide the baseline laboratory values measured during the 4 weeks prior to the start of the study drugs, specified below:~  * serum creatinine \< 1.5 times the upper normal limit;~ * total amylase \< 1.4 times the upper normal limit;~ * liver enzymes (AST, ALT) \< 4 times the upper normal limit.~Exclusion Criteria:~* Previous antiretroviral treatment.~* Suspected (acute) primary HIV infection starting less than six months before.~* Suspected or proven acute hepatitis in the 30 days prior to inclusion in the study. Subjects with chronic hepatitis are eligible provided their liver function enzymes \< 4 times the upper normal limit.~* Previous therapy with agents with a significant potential of systemic myelosuppression, neurotoxicity, pancreatotoxicity, liver toxicity or cytotoxicity in the 3 months prior to the start of the study, or expected need for requiring therapy on inclusion, or therapy with methadone or ribavirin/interferons or treatment with neurotoxic drugs or drugs affecting CYP 3A4.~* Patients under methadone program~* Abuse of alcohol or drugs, sufficient, in the investigator's opinion, to prevent an adequate compliance with the study treatment or that could increase the risk of developing pancreatitis or toxic hepatitis.~* Untreatable diarrhea (\> 6 loose stools/day for at least 7 consecutive days) within the 30 days prior to inclusion in the study.~* Pregnancy or nursing.~* History of bilateral peripheral neuropathy or signs and symptoms of bilateral peripheral neuropathy \> Grade 2 on screening.~* Inability to tolerate oral drugs.~* Any other clinical condition or previous therapy that, in the investigator's opinion, leads the patient to be inadequate for the study or unable to comply with the dosage requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: mHealth Mood Management Tool (Actify) to Improve Population-Level Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current smoker, averaging at least 5 cigarettes/day for the last 30 days~* Interested in quitting smoking in the next 30 days~* Experience downloading and using one or more apps on their smartphone~* Either screens negative (Patient Health Questionnaire - 9 Item \[PHQ-9\] score 0-4) for depression or screens positive for mild to moderate current depressive symptoms (PHQ-9 score 5-19)~* Willing and able to complete all study activities~* Comfortable reading and writing in English~* Have a mobile data plan and/or access to WiFi to support the use of the Actify app~* Reside in the US~* Have a smartphone either an iPhone (running iOS version 11 or higher) or an Android phone (running version 5.0 or higher)~Exclusion Criteria:~* Currently receiving behavioral treatment for depression (e.g., psychotherapy)~* Current use of a depression app~* Severe depression (PHQ-9 \>= 20)~* Receiving other treatment for smoking cessation~* Previous use of the QuitGuide app~* Current or recent (within the past year) enrollment in a Fred Hutch smoking cessation study~* Employees/family of investigator or study center~* Member of the same household as another participant~* Woman who is pregnant or breastfeeding, or planning to become pregnant~* Currently incarcerated~* Is ineligible per fraud prevention protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm I (Actify, text notifications) (Type: EXPERIMENTAL): Participants use Actify app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text notifications.
- Arm II (Current Standard Care, text notifications) (Type: ACTIVE_COMPARATOR): Participants use app for smoking cessation for 8 weeks. Participants also receive motivational messages and smoking cessation information via text notifications.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of On-demand Meteospasmyl® Use in Irritable Bowel Syndrome (IBS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female ambulatory patients, aged \>= 18 years~* with IBS as defined by Rome III criteria for more than 1 year and less than 10 years~* with a IBS-SSS between 175 and 400~Exclusion Criteria:~* Acute diarrhea, bowel disorders due to an underlying cause~* Patient treated with MeteoSpasmyl® within the past 6 months~* Recent history of gastro intestinal surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- meteospasmyl (Type: EXPERIMENTAL): None
- standard of care (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral Sulfate Solution on Bowel Preparation for Colonoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily participate and sign informed consent;~* Scheduling screening, surveillance, and diagnostic colonoscopy;~* Necessary body fluid and blood electrolyte balance (the test values of potassium, sodium, chlorine, calcium and magnesium in blood biochemistry during screening period should not exceed 10% of the normal range).~Exclusion Criteria:~* Subjects who used drugs that affect gastrointestinal dynamics, affect kidney function, or increase the risk of fluid retention or electrolyte disorders within 7 days before the start of the trial;~* Subjects with serious cardiac and cerebrovascular diseases, bronchial and lung diseases, suffering from metabolic disease or endocrine disease, abnormal blood clotting mechanism, malignant tumor, electrolyte abnormalities, epilepsy, Renal or liver dysfunction;~* Subjects with confirmed or suspected gastrointestinal obstruction, gastric retention, gastroparesis, gastric emptying disorder or acute gastrointestinal bleeding;~* Subjects with acute severe colitis (such as active severe inflammatory bowel disease, acute bacterial dysentery, diverticulitis, etc.);~* Subjects with a history of major gastrointestinal surgery (e.g. gastric bypass, gastric septal surgery, colostomy, colectomy, etc.);~* Subjects with constipation or suspected severe gastric motility disorder;~* Women with positive pregnancy tests or pregnancy plans, and women in lactation;~* Subjects who have participated in any other clinical trials within the last 3 months;~* Subjects with any other conditions that the investigator considered inappropriate for inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- OSS group (Type: EXPERIMENTAL): Bowel preparation for colonoscopy was performed using oral sulfate solution as laxative
- Polyethylene glycol group (Type: ACTIVE_COMPARATOR): Bowel preparation for colonoscopy was performed using polyethylene glycol as laxative

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete